Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplant relapse

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F09%3A%230000777" target="_blank" >RIV/65269705:_____/09:#0000777 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplant relapse

Original language description

utologous stem cell transplantation (ASCT) has an important role in the treatment of symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the last decade and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after ASCT have longer overall survival (OS). Patients and Methods: In this report we describe the long-term outcome of cohort 185 newly diagnosed MM patients (pts) treated with ASCT. We have analysed factors that might predict for long-term survival.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical Lymphoma & Myeloma

ISSN

1557-9190

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

—

UT code for WoS article

000272208300006

EID of the result in the Scopus database

—